Compare Stocks → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALPNNASDAQ:KMDANASDAQ:MBIONASDAQ:NXTCNASDAQ:SLGL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALPNAlpine Immune Sciences$64.430.0%$39.38$6.71▼$64.57$4.22B1.141.90 million shs2.46 million shsKMDAKamada$5.10+0.4%$5.78$4.08▼$6.53$293.10M1.0423,627 shs6,510 shsMBIOMustang Bio$0.37-2.6%$1.06$0.33▼$8.17$3.86M1.58177,756 shs199,542 shsNXTCNextCure$1.57+4.0%$1.72$0.98▼$2.57$43.80M0.4241,188 shs39,065 shsSLGLSol-Gel Technologies$0.94+10.5%$1.04$0.79▼$4.20$26.32M1.3329,239 shs4,553 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALPNAlpine Immune Sciences-0.06%+37.03%+81.73%+233.13%+762.92%KMDAKamada+3.67%-3.61%-13.46%-13.61%+8.32%MBIOMustang Bio+4.92%-26.10%-63.08%-72.37%-90.00%NXTCNextCure-7.93%-20.11%+4.86%+31.30%-5.03%SLGLSol-Gel Technologies-9.28%+1.40%-16.81%-24.17%-78.20%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALPNAlpine Immune Sciences1.4712 of 5 stars2.13.00.00.03.14.20.0KMDAKamada4.1095 of 5 stars3.55.00.00.02.71.73.1MBIOMustang Bio1.8472 of 5 stars3.55.00.00.02.30.00.0NXTCNextCure4.0421 of 5 stars3.53.00.04.61.11.71.3SLGLSol-Gel Technologies3.6445 of 5 stars3.85.00.00.03.51.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALPNAlpine Immune Sciences2.27Hold$50.33-21.88% DownsideKMDAKamada3.00Buy$11.00115.69% UpsideMBIOMustang Bio3.00Buy$17.254,549.60% UpsideNXTCNextCure3.00Buy$6.00282.17% UpsideSLGLSol-Gel Technologies3.50Strong Buy$8.00746.92% UpsideCurrent Analyst RatingsLatest KMDA, MBIO, ALPN, NXTC, and SLGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024ALPNAlpine Immune SciencesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/12/2024ALPNAlpine Immune SciencesSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$42.00 ➝ $65.004/11/2024ALPNAlpine Immune SciencesLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/11/2024ALPNAlpine Immune SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/11/2024ALPNAlpine Immune SciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral4/11/2024ALPNAlpine Immune SciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$47.00 ➝ $65.004/11/2024ALPNAlpine Immune SciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Sector Perform$41.00 ➝ $65.004/11/2024ALPNAlpine Immune SciencesWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Peer Perform4/9/2024ALPNAlpine Immune SciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$55.003/22/2024NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.003/20/2024NXTCNextCureNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALPNAlpine Immune Sciences$58.88M71.73N/AN/A$5.64 per share11.42KMDAKamada$142.52M2.06$0.44 per share11.49$4.25 per share1.20MBIOMustang BioN/AN/AN/AN/A$0.01 per shareN/ANXTCNextCureN/AN/AN/AN/A$4.10 per shareN/ASLGLSol-Gel Technologies$1.55M16.98N/AN/A$1.67 per share0.57Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALPNAlpine Immune Sciences-$32.18M-$0.64N/AN/AN/A-54.66%-15.54%-11.34%5/9/2024 (Estimated)KMDAKamada$8.28M$0.1534.0012.44N/A5.81%5.66%3.57%5/22/2024 (Estimated)MBIOMustang Bio-$51.60M-$6.00N/A∞N/AN/A-433.08%-146.39%5/10/2024 (Estimated)NXTCNextCure-$62.72M-$2.25N/AN/AN/AN/A-47.03%-42.59%5/2/2024 (Estimated)SLGLSol-Gel Technologies-$27.24M-$1.01N/AN/AN/A-1,331.01%-61.52%-53.75%5/10/2024 (Estimated)Latest KMDA, MBIO, ALPN, NXTC, and SLGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023NXTCNextCure-$0.54-$0.52+$0.02-$0.52N/AN/A3/18/2024Q4 2023ALPNAlpine Immune Sciences-$0.32$0.15+$0.47$0.15$6.90 million$30.85 million3/13/2024Q4 2023SLGLSol-Gel Technologies-$0.16-$0.17-$0.01-$0.17$0.27 million$0.45 million3/11/2024Q4 2023MBIOMustang Bio-$1.68-$0.71+$0.97-$0.71N/AN/A3/6/2024Q4 2023KMDAKamada$0.05$0.09+$0.04$0.09$37.71 million$36.43 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALPNAlpine Immune SciencesN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALPNAlpine Immune SciencesN/A7.867.86KMDAKamadaN/A3.431.64MBIOMustang BioN/A0.740.74NXTCNextCureN/A16.3816.38SLGLSol-Gel TechnologiesN/A9.109.10OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALPNAlpine Immune Sciences75.17%KMDAKamada20.38%MBIOMustang Bio9.95%NXTCNextCure42.65%SLGLSol-Gel Technologies26.18%Insider OwnershipCompanyInsider OwnershipALPNAlpine Immune Sciences42.30%KMDAKamada36.10%MBIOMustang Bio2.10%NXTCNextCure11.90%SLGLSol-Gel Technologies66.51%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALPNAlpine Immune Sciences14265.55 million37.82 millionOptionableKMDAKamada37857.47 million36.73 millionOptionableMBIOMustang Bio8010.39 million10.17 millionNot OptionableNXTCNextCure8227.90 million24.58 millionOptionableSLGLSol-Gel Technologies3627.86 million9.33 millionOptionableKMDA, MBIO, ALPN, NXTC, and SLGL HeadlinesSourceHeadlineSol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Down 17.8% in Marchamericanbankingnews.com - April 15 at 5:40 AMSol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Creamglobenewswire.com - April 1 at 7:00 AMSol Gel Technologies Ltd (SLGL)investing.com - March 23 at 11:58 AMSLGL May 2024 2.500 putfinance.yahoo.com - March 16 at 1:25 PMSol-Gel Technologies: Q4 Earnings Insightsbenzinga.com - March 14 at 1:48 PMSol-Gel Technologies Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Linefinance.yahoo.com - March 14 at 8:47 AMSol-Gel Technologies Ltd.: Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developmentsfinanznachrichten.de - March 14 at 3:47 AMSol-Gel Reports Full-Year 2023 Financial Results and Corporate Developmentsglobenewswire.com - March 13 at 7:00 AMSol-Gel Technologies Ltd. (SLGL) stock forecast and price targetfinance.yahoo.com - February 28 at 9:43 AMSol-Gel Technologies Stock (NASDAQ:SLGL), Quotes and News Summarybenzinga.com - February 22 at 10:05 AMOptimistic Buy Rating for Sol-Gel Technologies on Revolutionary Topical Treatment SGT-610’s Market Potentialmarkets.businessinsider.com - December 9 at 3:48 AMSol-Gel Technologies Ltd.: Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Studyfinanznachrichten.de - November 30 at 6:30 PMSol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Studyfinance.yahoo.com - November 30 at 8:29 AMSol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610finance.yahoo.com - November 28 at 9:36 AMIs Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Trading At A 24% Discount?finance.yahoo.com - November 20 at 7:19 AMSol-Gel Technologies GAAP EPS of -$0.21 beats by $0.02, revenue of $0.21M misses by $0.48Mmsn.com - November 9 at 5:31 PMSol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 9 at 7:27 AMZacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologiesfinance.yahoo.com - October 31 at 9:35 AMIs Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Invest In Growth?finance.yahoo.com - October 10 at 10:05 AMSol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - August 30 at 2:55 PMHC Wainwright & Co. Maintains Sol-Gel Technologies (SLGL) Buy Recommendationmsn.com - August 15 at 5:07 AMExpert Ratings for Sol-Gel Technologiesmarkets.businessinsider.com - August 11 at 4:26 PMSol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimatesfinance.yahoo.com - August 10 at 2:04 PMSol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 10 at 9:03 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAlpine Immune SciencesNASDAQ:ALPNAlpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.KamadaNASDAQ:KMDAKamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Mustang BioNASDAQ:MBIOMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.NextCureNASDAQ:NXTCNextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.Sol-Gel TechnologiesNASDAQ:SLGLSol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; SGT-610, a rare disease for the treatment of Gorlin Syndrome which has completed Phase II clinical trials; and Erlotinib and Tapinarof to treat other rare skin indications. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.